Chief Medical Officer
Lynne Kelley is the Chief Medical Officer for Servier Pharmaceuticals helping to drive strategy and enable the business to achieve its goals for sustainable growth.
Lynne is a general and vascular surgeon by training, bringing over 15 years of industry experience across a wide array of therapeutic areas including oncology and rare and orphan diseases. She has served as Chief Medical Officer for Senseonics, Histogenics, and most recently X4 Pharmaceuticals. Lynne has led global teams of medical professionals spearheading innovation, due diligence, clinical trials (of novel drug products, biologics, medical devices, and drug-device combinations), safety evaluations, product development and key opinion leader management.
Lynne received her Bachelor of Arts in Biology from Boston University. She continued her education pursuing her Doctor of Medicine from Dartmouth Medical School, where she is now a member of the Advisory Board for the Center for Health Equity. She is also on the Board of Directors at D-Rev.
To learn more about Lynne connect with her on LinkedIn.
More from Servier
Servier Pharmaceuticals is a privately held pharmaceutical company focused on oncology. Everything we do is to bring the promise of tomorrow to the patients we serve.Learn More
Servier Pharmaceuticals is an independent, privately held United States company launched by Servier Group, a unique global organization, and is governed by a non-profit foundation.Learn More
Servier has a 65-year history of helping provide innovative medicines to patients globally. In the United States, Servier intends to uphold and build upon that history.Learn More